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Abstract
Background: As playing important roles in gene regulation, microRNAs (miRNAs) are believed as indispensable involvers in
the pathogenesis of myocardial infarction (MI) that causes significant morbidity and mortality. Working on a hypothesis that
modulation of only some key members in the miRNA superfamily could benefit ischemic heart, we proposed a microarray
based network biology approach to identify them with the recognized clinical effect of propranolol as a prompt.
Methods: A long-term MI model of rat was established in this study. The microarray technology was applied to determine
the global miRNA expression change intervened by propranolol. Multiple network analyses were sequentially applied to
evaluate the regulatory capacity, efficiency and emphasis of the miRNAs which dysexpression in MI were significantly
reversed by propranolol.
Results: Microarray data analysis indicated that long-term propranolol administration caused 18 of the 31 dysregulated
miRNAs in MI undergoing reversed expression, implying that intentional modulation of miRNA expression might show
favorable effects for ischemic heart. Our network analysis identified that, among these miRNAs, the prime players in MI were
miR-1, miR-29b and miR-98. Further finding revealed that miR-1 focused on regulation of myocyte growth, yet miR-29b and
miR-98 stressed on fibrosis and inflammation, respectively.
Conclusion: Our study illustrates how a combination of microarray technology and functional protein network analysis can
be used to identify disease-related key miRNAs.
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Introduction
Increasing lines of evidences suggest that microRNAs (miRNAs)
are involved in modulating cardiac processes and in the
progression of heart disease [1]. Because of the large number of
miRNAs, microarray technology has been extensively applied in
revealing global miRNA expression changes in human models of
heart disease associated with cardiac hypertrophy, heart failure,
and myocardial infarction [2]. In the present study, we proposed a
microarray based network biology approach to identify the key
miRNAs most likely related to myocardial infarction (MI) by
integrating miRNA expression and protein-protein interaction
(PPI) network data.
MI is characterized by a loss of excitability associated with ionic,
functional, and metabolic abnormalities. Many clinical trials have
verified that antiarrhythmic drugs such as sodium-channel,
potassium-channel or calcium-channel blockers cannot prevent
the morbidity associated with MI induced malignant arrhythmias
[3,4]. In contrast, b-adrenoceptor blockers have proven successful
in preventing sudden cardiac death in patients with MI [5-7];
however, the essential mechanism underlying the beneficial effects
of these agents remains unclear. As a vital node in posttranscrip-
tional regulation of many biological functions, miRNAs are
considered as important regulators of human physiological and
pathological conditions [8]. Consequently, it is entirely possible
and perhaps likely that the alterations of miRNA expression may
be involved in the beneficial therapeutic effects of agents such as
propranolol, a b-adrenoceptor blocker. In order to determine the
miRNAs most highly related to MI, we employed miRNA chips to
evaluate the global miRNA expression of a MI rat model
produced by the occlusion of the left anterior descending coronary
artery. Propranolol was chronically administered to induce
reversal of MI and global expression change of miRNAs expressed
in rat heart was determined. Multiple network analyses were then
employed to quantitatively access the regulatory capacity,
efficiency and emphasis of the miRNAs which dysexpression in
MI were significantly reversed by propranolol.
In a recent review, Pan et al. discussed the possibility of taking
miRNAs as potential therapeutic targets for treating cardiac
diseases, especially ischemic heart disease. Such an opinion was
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be obtainable by modulating some key regulators [9]. Through
miRNA microarray and protein interaction network data
integration, our approach presented here could not only pick
out key miRNAs involved in MI but also bring novel insight in the
pathological mechanisms of MI from the miRNA aspect.
Intriguingly, as a vital node in posttranscriptional regulation,
miRNAs participate in many cellular pathways in both physio-
logical and pathological conditions [10]. Therefore, undoubtedly,
the method presented here is also applicable to other human
diseases.
Results
Propranolol affected miRNA expression profile of MI
The beneficial effect of propranolol on MI was investigated
using four randomized groups of experimental rats: control,
myocardial infarction (MI), MI with propranolol treatment (MI-
PRO) and non-MI with propranolol treatment (NMI-PRO). Oral
administration of propranolol at a daily dose of 10 mg/kg
significantly reduced the infarct size of the left ventricle in rats
with MI (Figure 1A). Among the 102 miRNAs which can be
detected in all miRNA arrays, almost half of them underwent
obvious downregulation in NMI-PRO group while only 12
miRNAs did so in MI group (Figure 1B). The propensity of
miRNA targeting positive regulatory motifs [11] implied the
prodigious miRNA expression change was consistent with the
favorable effects of propranolol on MI (Figure 1B). The expression
similarity of 0.39 (MI-PRO versus NMI-PRO) suggested the
benefits of propranolol to MI were associated with the rectified
miRNA expression profile (Figure 1B, right upper). Among the 31
dysregulated miRNAs in MI (Table S1), 18 PRmiRs (propranolol-
reversed miRNAs, PRmiRs) were found in MI rats administered
with propranolol (Fold change.1.5, MI-PRO versus MI).
Static topological analysis identified miRNAs with
enhanced regulation
To perform static topological analysis, a cardiac-specific PPI
network was established in advance by importing heart expressed
genes of MI Wistar rats (accession number: GDS808) [12] into
STRING [13]. The final network was comprised of 2846 nodes
and 22163 interactions, when determined at the relatively high
confidence level of 0.7. After the validated and predicted target
genes [14,15] associated with the MI-dysregulated miRNAs listed
in Table S1 were imported into the network, the Cytoscape [16]
plug-in NetworkAnalyzer [17] was applied for calculating static
score (See MATERIALS AND METHODS). There were 10
PRmiRs and 7 non-PRmiRs assigned with static scores of more
than 0.6 suggesting enhanced regulation by them (Figure 2A). To
further confirm the result of static analysis upon the cardiac-
specific network, a larger PPI network was also established by
Figure 1. Effects of propranolol on the infarct size and miRNAs expression. A. Effects of propranolol on the infarct size in rats with
myocardial infarction. Left panel: the white portion of the coronal sections of the left ventricular wall represents the infarct area. Right panel: the size
of infarct area was expressed as the percentage of a standard coronal section. **p,0.01 vs. MI (two-way paired t-test), n=5. B. Count of miRNAs with
expression levels varied by at least 60.5 from the levels in Control. The right upper heatmap shows the miRNA expression similarity between groups.
MI, myocardial infarction; MI-PRO, myocardial infarction-propranolol; NMI-PRO, non-myocardial infarction-propranolol. C. Quantification of miR-1
expression. Relative level of miR-1 normalized to control; ***p,0.0001 vs. control; ##p,0.01 vs. MI (two-way paired t-test), n=8.
doi:10.1371/journal.pone.0014736.g001
MicroRNA Expression Analysis
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e14736importing the target genes of all the chip detected miRNAs into
STRING. As a result, we obtained the miRNA-targeted PPI
network, which was comprised of 4940 nodes and 88776
interactions at the same confidence level of 0.7. Similarly, we
calculated the static scores of the MI-dysregulated miRNAs
(Figure 2A). Notably, only 4 PRmiRs showed strengthened
regulation in both of the PPI networks. They were miR-1, miR-
21, miR-195 and miR-200c. And 2 non-PRmiRs let-7f and miR-
208 did so.
To investigate whether strengthened control made miRNAs more
efficient to overcome the robustness of the PPI network itself, we
performed a dynamic perturbation analysis to virtually simulate the
effect of altered miRNA expression on global free protein
concentration in the cardiac-specific PPI network. The gene
expression data (accession number: GDS808) was imported into
the network as substitute nodes as attributed by ProteinAbundance
[18]. As dynamic score was introduced here (See MATERIALS
AND METHODS), the Cytoscape plug-in PerturbationAnalyzer
quantified the regulatory efficiency of the MI-dysregulated miRNAs
against the network robustness. Interestingly, we found that dynamic
scores were significantly associated with the mean target gene
abundances (log2, p=0.0016), instead of static scores (Figure 2B and
C). This result implied that excessive target gene abundance could
dilute the regulatory performance of a miRNA, even though the
important roles of its interacted genes in biological regulation might
be found [19]. Among the 18 PRmiRs, miR-98 showed the most
efficientgene regulation(dynamicscore:0.778,Figure 2C).Asastatic
score of 0.63 indicated its enhanced regulation on the cardiac-specific
PPI network, abnormal expression of miR-98 in MI might strongly
imbalance its controlled biological modules.
ClusterOne analysis discovered the regulatory emphasis
of miRNAs
With an opinion that a miRNA with too scattering gene
regulation might not likely induce significant phenotype, the
ClusterOne Cytoscape plug-in [20] was used to disclose the
enriched functional module that was comprised of proteins
encoded by target genes of the 10 PRmiRs which enhanced
regulation was found on the cardiac-specific PPI network
(Figure 3). With the Gene Prospector tool in the HuGE Navigator
database [21] applied, we established the association between the
modules and disease phenotype ischemia. The modules regulated
by miR-1, miR-29b and miR-98 contained more proteins encoded
by ischemia related genes (Figure 3). The DAVID functional
annotation clustering tool [22] then identified the significantly
over-represented biological process each module was involved in
Figure 2. Results of static and dynamic network analyses. A. Static scores of the 29 dysregulated miRNAs in myocardial infarction.
B. Correlation between static score and dynamic score. C. Correlation between average target gene abundance (log2) and dynamic score. non-PRmiR,
dysregulated miRNA in myocardial infarction which expression could not be reversed by propranolol; PRmiR, propranolol-reversed miRNAs.
doi:10.1371/journal.pone.0014736.g002
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regulation of myocyte growth, yet miR-29b and miR-98 put their
regulatory emphases upon fibrosis and inflammation, respectively.
Discussion
In recent years, miRNAs have been identified as key regulators
of protein expression and have been implicated in many
physiologically relevant cellular pathways [8]. Altered miRNA
expression has been implicated in the cardiovascular system and
changes in miRNAs have been correlated with cardiac diseases
[23]. In the present study, an innovative integrative analysis of
protein-protein interaction and miRNA expression data was
undertaken to search for the miRNAs that might be key regulators
of MI, a common cause of heart failure. In particular, we
employed a long-term propranolol-administered rat model of MI
with a notion that the favorable effects of propranolol, a b-
adrenoceptor blocker, could provide us some useful clues. MiRNA
microarray analysis showed that the alteration of miRNAs
expression was consistent with the favorable effects of propranolol
(Figure 1A and B). Further finding revealed that propranolol
successfully reversed the altered expression of two-thirds of the
dysregulated miRNAs in MI (Table S1).
To quantitatively describe gene regulation of miRNAs, we
introduced two parameters static and dynamic scores. As the
cardiac-specific and miRNA-targeted PPI networks were established
byretrieving proteininteractionsofhighconfidence scoresderivedby
benchmarking the performance of the predictions against KEGG
[24], reference set of associations from STRING [13], static score
inherently scaled the regulatory capacity of each dysregulated
miRNAs (Figure 2A). Two topological parameters degree and
neighborhood connectivity were integrated into the calculation of
static score. By counting the number of neighbors connected to a
given node, the parameter degree reflects its status in cellular
functions [25]. Similarly, high neighborhood connectivity of a node
means the likelihood that it is connected with a highly connected
protein and involved in important cellular functions [26]. If static
score of 0.6 reflected moderate regulation by a miRNA, five PRmiRs
and two non-PRmiRs performed enhanced gene regulation upon
both of the PPI networks (Figure 2A). To access the regulatory
efficiency of each dysregulated miRNAs, a dynamic perturbation
analysis was designed by applying the PerturbationAnalyzer
Cytoscape plug-in [18], a convenient tool for calculating the
perturbation effect in a PPI network by comparing equilibrium
states.Toperformsuchasimulation,theconcentrationsofproteinsin
the PPI network need to be known. Unfortunately, the genome-wide
protein abundances in the rat are not yet available [18]. Instead, we
used gene expression data found in the GEO database [12] as an
approximation of protein abundance for PertubationAnalyzer
calculations. This rationale for this approach is based, in part, on
the previous findng that in yeast a direct relationship exists between
mRNA levels and protein levels [27]. The result of dynamic
perturbation simulation suggested that efficient gene regulation
executed by a miRNA was inversely correlated with its mean target
gene abundance and not associated with its regulatory capacity in
essential (Figure 2B and C). Our finding was consistent with the
previous work of Arvey et al [19].
To investigate the regulatory emphasis of individual PRmiRs with
enhanced regulation upon the cardiac-specific PPI network, the
ClusterOne analysis was performed to discover the functional PPI
modules they strongly controlled (Figure 3). The DAVID functional
annotation clustering tool [22] and the gene evidence retrieved from
the HuGE Navigator database [21] jointly identified three PRmiRs
which were more closely related to MI (Figure 3). They were miR-1
emphasizing on cell growth regulation, miR-29b stressing on fibrosis
and miR-98 focusing on inflammation. Approximately 60% of the
target genes of them were assigned comparatively small p-values or
experimentally validated (See MATERIALS AND METHODS).
This made our conclusion credible (Table S2).
There are increasing lines of evidences to suggest that miR-1
might be a vital regulator of MI [28,29]. Lu et al. confirmed that the
administration of propranolol could reverse the expression of miR-1
in ischemic rat heart and inhibition of miR-1 could provide
ischemic cardioprotection [30]. Taken together, these studies
provide functional links between miR-1 and MI, which is consistent
with its higher static score in our network analysis. It was recently
demonstrated that miR-29b wasdramaticallydown-regulatedinthe
region of the fibrotic scar after MI and collagen expression in the
Figure 3. Results of ClusterOne analysis. A-C. Largest functional modules regulated by miR-1, miR-29b and miR-98, respectively. The yellow
nodes represent proteins encoded by genes that are associated with ischemia.
doi:10.1371/journal.pone.0014736.g003
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[31]. In contrast, we found an elevation in miR-29b. Although the
important role of miR-98 in inflammatory response of cholangio-
cyte has been verified [32], the experimental evidence of its
involvement in inflammation during myocardial ischemia still lacks.
In conclusion, while the PPI network presented here may include
some false positive interactions and false prediction of miRNA gene
targets, it is hoped that such a systemic analysis can help confirm
and identify the key miRNAs that was related to MI.
Materials and Methods
Drugs and animals
Propranolol (Sigma-Aldrich, St Louis, MO, USA) was firstly
dissolved in 20% dimethyl sulfoxide (DMSO), and then diluted in
PBS to the final concentration before the experiment. The final
concentration of DMSO was 0.02% and shown no effects on
cardiac functions (data not shown). Other reagents were purchased
from Sigma (St Louis, MO, USA). All procedures involving the use
of animals in this study complied with the regulations and protocols
of the ethic committees of Harbin Medical University and the
Guide for the Care and Use of Laboratory Animals of the US
National Institutes of Health (NIH Publication No. 85–23, revised
1996). Male Wistar rats (250–300 g) were conditioned for one week
at room temperature, with 5565% humidity and a 12 h cycle of
light/dark. They were allowed free access to food and tap water.
The rats were randomly divided into 4 groups: control, myocardial
infarction (MI), myocardial infarction-propranolol (MI-PRO), and
non-myocardial infarction-propranolol (NMI-PRO). All the rats
were anesthetized with pentobarbital (40 mg/kg, i.v.), and then rat
MI model was established by occluding left anterior descending
coronary artery under sterile conditions. A daily oral dose of
10 mg/kg of propranolol was administered to MI-PRO and NMI-
PRO rats for 2 months before the experiment. After the rats were
sacrificed, the infarct zone of the left ventricle was rapidly isolated
and used for the miRNA microarray experiment. The open chest
procedures were also experienced by control and NMI-PRO
animals, but the coronary artery occlusion was not applied to them.
Myocardial infarct size measurement
Size of the infarct area of the left ventricle in rats was measured
as described previously [33].
MiRNA microarray
The microarray assay for miRNAs profiling was conducted by
the China Shanghai Kangcheng Technology Co, Ltd. In total, left
ventricular samples of eight rat hearts from each group were
pooled and in the end four miRNA chips were prepared. The
microarray data is MIAME compliant (accession number:
GSE18129). Between groups (MI, MI-PRO and NMI-PRO),
expression similarities of miRNAs with expression levels varied by
at least 60.5 from the levels in control (dysregulated miRNA,
dmiR) were calculated as followed:
Expression similarity~
NdmiR(consistent in group x and y)
NdmiR(group x)zNdmiR(group y){NdmiR(consistent in group x and y)
Static and dynamic network analyses
To perform static and dynamic network analyses upon
miRNAs, two PPI networks were established in this study. The
cardiac-specific PPI network was built by retrieving relatively high
confident protein interactions (confidence score: 0.7) from
STRING and gene expression data for MI Wistar rat hearts from
GEO (accession number: GDS808). To build the miRNA-targeted
PPI network, the target genes of miRNAs detected by the miRNA
chip were retrieved from Microcosm and their protein products
were combined for online search for PPIs in STRING. Again, the
confidence score of 0.7 was chosen. Notably, for STRING did not
permit long list submission, we disassembled the entire list. The
network depth of 2 was chosen so that every direct neighboring
node could be involved in the downloaded sub-network. The final
merged network was then established by applying Cytoscape 6.2.3.
To evaluate the regulatory capacity of individual miRNAs, the
Cytoscape plug-in NetworkAnalyzer was applied to calculate two
topological parameters degree and neighborhood connectivity for
every node in the two networks. After importing the information of
the validated [14] and predicted [15] target genes of a miRNA
into the networks, the normalized mean degree and neighborhood
connectivity values of the nodes representing proteins encoded by
its target genes were calculated with network mean value as
background. Finally, the miRNA obtained an integrated param-
eter static score as the sum of the normalized mean degree and
neighborhood connectivity values was subtracted by 3.3. Higher
static score means stronger regulation exerted by a miRNA. In
Microcosm, p-value is computed to identify significant correlation
between miRNA and target genes by considering the genomic
miRanda score distribution. If a p-value is small, it means that the
corresponding prediction result is likely correct [34]. For each
analyzed miRNA, the percentage of validated and more correctly
predicted genes (p-value,0.01) in the networks was calculated.
To evaluate the regulatory efficiency of a miRNA against the
network robustness, the gene expression data of MI Wistar rat
hearts (accession number: GDS808) was imported in the network
as the substitute node attribute of ProteinAbundance. The
Cytospcape plug-in PerturbationAnalyzer was used to access the
global effect of altered miRNA expression upon network
homeostasis as proteins encoded by its targeted genes were
selected as perturbation sources in the manual perturbation mode.
After perturbation, the ratio of the property Perturbed subgroup
size at 2.0 and 1.2 subgroup thresholds was calculated as dynamic
score. A low dynamic score means that network robustness can
more easily resist the impact of altered miRNA expression.
ClusterOne analysis
To disclose the regulatory emphasis of a given miRNA, the
Cytoscape plug-in ClusterOne was applied to discover the significantly
overlapping regions in the PPI network which was only comprised of
proteins encoded by its target genes. The PPIs were retrieved from
STRING as confidence score of 0.7 was chosen. As the default settings
of ClusterOne were unchanged, the largest module within each
network was selected for further biological process analysis. The
DAVID functional annotation clustering tool was responsible for
investigating the significantly over-represented biological process
proteins in the module might participate in. The functional annotation
‘GOTERM_BP_ALL’ was only selected. Meanwhile, the Gene
Prospector tool in the HuGE Navigator database was applied to
explore the experimentally validated association between their
corresponding genes and the disease-phenotype ischemia.
Supporting Information
Table S1. The 31 dysregulated miRNAs in myocardial
infarction.
Found at: doi:10.1371/journal.pone.0014736.s001 (0.05MBDOC)
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DOC)
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